The Absorption, Distribution, Excretion, and In Vitro Hepatic Microsomal Metabolism of the Novel CDK Compound XMD12 in Sprague-Dawley Rats.

ABSTRACT: Background: Cyclin-dependent kinase 4/6 (CDK4/6) represents one of the clinically validated and therapeutically effective anticancer targets. Methods: This study established a rapid and sensitive HPLC-MS/MS method for quantitative determination of XMD12, a novel CDK4/6 inhibitor developed in our laboratory, in various rat biological matrices including plasma, tissue homogenates, urine and feces. The experimental design comprised three distinct phases: pharmacokinetic evaluation in 10 Sprague-Dawley SD rats (5 receiving 2.0 mg/kg intravenous injection via tail vein and 5 administered 10.0 mg/kg by gastric gavage); tissue distribution assessment in 25 SD rats following a single 20 mg/kg gastric gavage; and an excretion study in 5 SD rats following a single 20 mg/kg gastric gava

SUBMITTER: Zheng XH 

PROVIDER: S-EPMC12736570 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature